Matching articles for "immunotherapy"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • November 25, 2024; (Issue 1716)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Omalizumab (Xolair) for Food Allergy
The Medical Letter on Drugs and Therapeutics • April 1, 2024; (Issue 1699)
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also...
Omalizumab (Xolair – Genentech), a recombinant
anti-IgE monoclonal antibody FDA-approved for
treatment of allergic asthma, chronic rhinosinusitis
with nasal polyps, and chronic urticaria, has now
also been approved for use in conjunction with food
allergen avoidance to reduce IgE-mediated food
allergic reactions caused by accidental exposure in
patients ≥1 year old. Omalizumab is the first drug to
be approved in the US to reduce allergic reactions to
more than one food. Palforzia, an oral peanut allergen
powder, was approved in 2020 to mitigate allergic
reactions caused by accidental peanut exposure in
patients with a confirmed peanut allergy.
Cyclosporine Ophthalmic Emulsion (Verkazia) for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • May 1, 2023; (Issue 1675)
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to...
The FDA has approved Verkazia (Santen), a 0.1%
ophthalmic emulsion formulation of the calcineurin
inhibitor cyclosporine, for treatment of vernal
keratoconjunctivitis (VKC). Verkazia is the first
product to be approved in the US for this indication.
Drugs for Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • April 19, 2021; (Issue 1622)
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table...
The choice of drugs for treatment of allergic rhinitis
depends on the severity of symptoms and whether
they are intermittent or persistent (see Table 1).
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Drugs for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • June 15, 2020; (Issue 1600)
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and...
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving by
adolescence, but sometimes persisting into (or first
appearing in) adulthood or even old age.
Peanut Allergen Powder (Palforzia)
The Medical Letter on Drugs and Therapeutics • March 9, 2020; (Issue 1593)
The FDA has approved peanut allergen powder-dnfp
(Palforzia – Aimmune) for use as oral immunotherapy
to mitigate allergic reactions, including anaphylaxis,
caused by accidental peanut exposure in patients...
The FDA has approved peanut allergen powder-dnfp
(Palforzia – Aimmune) for use as oral immunotherapy
to mitigate allergic reactions, including anaphylaxis,
caused by accidental peanut exposure in patients with
a confirmed peanut allergy. It is the first drug to be
approved in the US for this indication; Viaskin Peanut,
an immunotherapy patch, is under FDA review for the
same indication.
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • February 26, 2018; (Issue 1541)
The FDA has approved Odactra (ALK), a sublingual
allergen extract, for immunotherapy in adults 18-65
years old with house dust mite (HDM)-induced allergic
rhinitis, with or without conjunctivitis. Odactra is...
The FDA has approved Odactra (ALK), a sublingual
allergen extract, for immunotherapy in adults 18-65
years old with house dust mite (HDM)-induced allergic
rhinitis, with or without conjunctivitis. Odactra is the
first sublingual allergen extract to be approved in the
US for this indication. Three other sublingual allergen
extracts were approved earlier (see Table 1).
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed...
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed here.
Drugs for Allergic Disorders
The Medical Letter on Drugs and Therapeutics • May 8, 2017; (Issue 1520)
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma. H1-ANTIHISTAMINES — Oral – Oral...
Allergic rhinitis can be classified as seasonal,
perennial, or episodic. It is often associated with
allergic conjunctivitis, rhinosinusitis, and asthma.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
H1-ANTIHISTAMINES — Oral – Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • February 1, 2012; (Issue 114)
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers....
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers. Non-chlorinated
hydrofluoroalkane (HFA) propellants, which do
not deplete the ozone layer, are being used instead.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 76)
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become...
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • May 1, 2005; (Issue 33)
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other...
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740).